Grey-market
#peptides: an emerging public health challenge | InSight+
https://insightplus.mja.com.au/2026/15/grey-market-peptides-an-emerging-public-health-challenge/ “Within Australian clinical practice, people, particularly those aged in their 20s and 30s, are increasingly inquiring about or using these unregulated compounds. Drivers of uptake include cost barriers of approved GLP-1RA therapies, limited PBS eligibility criteria, and the perception that grey-market alternatives offer equivalent therapeutic benefit at lower cost or access to more effective novel agents unavailable in Australia.”